Temaz and Multihance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temaz (temazepam) and Multihance (gadobenate dimeglumine). Common drug interactions include nephrogenic systemic fibrosis among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Temaz and Multihance. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 42,293 Temaz users. Check the latest studies of Temaz.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

On Jul, 31, 2026

35 people who take Temaz and Multihance together, and have interactions are studied.

What are the common drug interactions of Temaz and Multihance, by gender? *:

female:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Emotional distress
Mobility decreased (ability to move is reduced)
Pain
Anxiety
Skin discolouration (change of skin colour)
Asthenia (weakness)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
General physical health deterioration (weak health status)
Oedema peripheral (superficial swelling)

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Muscle tightness
Myosclerosis (hardening of muscle tissue)
Oedema peripheral (superficial swelling)
Skin induration (an abnormally hard spot or area on the skin)
Skin tightness
Activities of daily living impaired
Fatigue (feeling of tiredness)
Frustration (a form of poorly expressed anger)

What are the common drug interactions of Temaz and Multihance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Emotional distress
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
General physical health deterioration (weak health status)
Mobility decreased (ability to move is reduced)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Scar
Bronchopneumonia (inflammation of the lungs, arising in the bronchi or bronchioles)

40-49:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Anxiety
Emotional distress
Injury
Pain
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Joint contracture (a permanent shortening of a muscle or joint)
Joint range of motion decreased (disease of joint movement)
Muscle fibrosis (fibrous muscle)

50-59:

Anxiety
Asthenia (weakness)
Emotional distress
Joint range of motion decreased (disease of joint movement)
Muscle tightness
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Quality of life decreased
Skin discolouration (change of skin colour)
Fatigue (feeling of tiredness)
Skin hyperpigmentation (disorders affect the colour of your skin)

60+:

Hypersensitivity
Hypotension (abnormally low blood pressure)
Hypoxia (low oxygen in tissues)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 9 people, 25.71%
Nuclear Magnetic Resonance Imaging Abdominal: 9 people, 25.71%
Kidney Transplant Rejection: 4 people, 11.43%
Osteomyelitis (infection of bone): 2 people, 5.71%
Diabetic Foot: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Temaz and Multihance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously